IN NAD and Migraine Headaches: A Case Report

Intranasal Administration of Nicotinamide Adenine Dinucleotide Alleviates Headaches Associated with Migraine Pain: A Case Report

 Thompson, A., DiBlasio, P., Dyess, G.A., Broom, S.L., Mestayer, R.F, presented at Mississippi Academy of Sciences Conference, March 2022


An 87-year-old woman with a 50-year history of migraines received NAD/Lidocaine at 100 mg/mL, 0.5% per protocol of 0.5 mL, intranasally into each nostril via sphenocatheter. The patient also was prescribed Real NAD+ (150mg/day) sublinguql lozenges over a three-month period. 

Follow-up interviews were conducted at one week, six weeks, three months, and one year, with the following results:

The patient tolerated the treatment well, reported no adverse effects, and has not had a single recurring migraine.

MAS 2022 ATPDGDSB poster